Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs
Rhea-AI Filing Summary
Insider Robert Blum reported planned and recent disposals of Cytek Biosciences common stock via Form 144. The filing lists 45,000 Restricted Stock Units to be sold and shows two reported disposals in the past three months: 36,601 shares for $2,274,752.15 and 7,931 shares for $481,570.32. The cover lists an aggregate value of $2,965,950.00 and a figure of 123,162,807 shown alongside the 04/01/2026 date.
Positive
- None.
Negative
- None.
Insights
Form 144 shows an insider disposition of equity through RSUs and recent open-market sales.
The filing lists 45,000 Restricted Stock Units as the securities to be sold and records two recent disposals: 36,601 shares and 7,931 shares, with aggregate reported proceeds in the filing.
These entries are routine disclosures of planned and completed sales under Rule 144; cash‑flow treatment and whether sales were part of a prearranged plan are not stated in the excerpt. Subsequent SEC filings or broker disclosures would provide execution details.